FT839
Advanced Solid Tumors
Phase 1Active
Key Facts
About Fate Therapeutics
Fate Therapeutics is on a mission to deliver 'Better Cells for Better Therapies®' by leveraging its industry-leading induced pluripotent stem cell (iPSC) platform to create off-the-shelf, uniformly engineered cell products. The company has established a broad clinical pipeline targeting hematologic malignancies, solid tumors, and autoimmune disorders, with multiple programs in Phase 1/2 development. Its core strategy is to disrupt the cell therapy paradigm by moving from bespoke, patient-specific manufacturing to a scalable, industrialized model that promises greater consistency, lower cost, and immediate patient access.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |